Femasys regains Nasdaq minimum bid price compliance

Femasys Inc. (NASDAQ: FEMY) announced it received formal notice from The Nasdaq Stock Market LLC confirming the company has regained compliance with Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on the exchange.

Nasdaq confirmed the matter is now closed, according to a press release from the Atlanta-based biomedical company.

Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys, said, "Regaining compliance with Nasdaq's continued listing requirements is an important development for Femasys and our shareholders. With this matter now closed, we remain focused on advancing our strategic priorities, expanding access to our innovative reproductive health solutions and building long-term value."

You May Also Be Interested In

• Votorantim agrees to sell Nexa Resources stake to Boliden
• FibroBiologics regains Nasdaq compliance for bid price rule
• Alcon prices €500M senior notes due 2033